Adjuvant Ribociclib With Endocrine Therapy in Hormone Receptor+/HER2- Intermediate Risk Early Breast Cancer

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2018
This is an international, multi-center, randomized, double-blinded, placebo-controlled clinical study evaluating the efficacy and safety of ribociclib with endocrine therapy as an adjuvant treatment in patients with hormone receptor-positive, HER2-negative, intermediate risk breast cancer.
Epistemonikos ID: ff3fa6c0251cd321cf08263ac0879d8e250c0143
First added on: May 20, 2024